Breaking News
November 15, 2018 - CityU develops first microarrayed 3D neuronal culture platform
November 15, 2018 - Expert suggests ways to control uncomfortable vaginal symptoms in diabetic women
November 15, 2018 - New edition of Red Journal focuses on roles of imaging in radiation oncology
November 15, 2018 - Doctors Aren’t Promoting Breastfeeding’s Cancer-Protection Benefit
November 15, 2018 - Technique to ‘listen’ to a patient’s brain during tumour surgery
November 15, 2018 - Seven-year-old returns to life as a “normal, healthy child” following bone marrow transplant
November 15, 2018 - AMSBIO expands range of high quality FFPE cancer cell line controls
November 15, 2018 - Exploring NMR Spectroscopy Applications through Interesting Infographics
November 15, 2018 - Chapman University wins additional $2.9 million NIH grant to study Alzheimer’s disease
November 15, 2018 - Microgel powder reduces infection and promotes healing
November 15, 2018 - Suicidal patients with prescribed access to psychotropic drugs should be closely monitored
November 15, 2018 - Nitric oxide-releasing technology shows potential to reduce healing time of diabetic foot ulcers
November 15, 2018 - Mass shootings may trigger unnecessary blood donations
November 15, 2018 - From heart disease to cancer: New study tracks shift of county death rates
November 15, 2018 - Preventing falls with new sensor technology
November 15, 2018 - Promising technology could improve detection, diagnosis of fatal ovarian cancer
November 15, 2018 - AAP updates concussion recommendations for children and teens
November 15, 2018 - Two genomic tests help identify most effective treatment for breast cancer patients
November 15, 2018 - Researchers evaluate efficacy of salivary biomarkers for early detection of oral cancer
November 15, 2018 - NIH awards $3.5 million to continue development of robotic system for treating brain tumors
November 15, 2018 - Researchers succeed in building protein nanotubes from tiny scaffolds
November 15, 2018 - Rectal bleeding
November 15, 2018 - Nasal delivery of weight-loss hormone eases breathing problems in sleeping mice
November 15, 2018 - $9.6 million grant to fund research on vascular risk factors for brain aging, dementia | News Center
November 15, 2018 - Gum disease linked with diabetes
November 15, 2018 - Study identifies unique functional brain networks associated with ASD behaviors in infancy
November 15, 2018 - EU and industry-funded project aims to personalize diabetes treatment
November 15, 2018 - NIH researchers shed light on causes of HBV-associated acute liver failure
November 14, 2018 - FDA Alert: Implanted Pumps: Safety Communication
November 14, 2018 - Weight loss & acute Porphyria
November 14, 2018 - Researchers identify three sub-types of depression
November 14, 2018 - The puzzle of a mutated gene lurking behind many Parkinson’s cases | News Center
November 14, 2018 - The mystery viruses far worse than flu
November 14, 2018 - Research highlights physical changes in the brain of self-injuring teen girls
November 14, 2018 - Speed and error rate of DNA synthesis influenced by DNA structure
November 14, 2018 - Cranberry consumption modifies impact of animal-based diet on gut health
November 14, 2018 - £500,000 grant could pave way for new antibiotic to battle against drug-resistant superbugs
November 14, 2018 - Trump Administration Finalizes Birth Control Coverage Opt-Out
November 14, 2018 - Modern life offers children almost everything they need, except daylight
November 14, 2018 - Getting better: A patient is more than a collection of numbers
November 14, 2018 - 20 Americans Die Each Day Waiting For Organs
November 14, 2018 - First bifacial molecule can invade double-stranded DNA or RNA
November 14, 2018 - Study finds lack of safety data for using flowers in cooking
November 14, 2018 - Statistical methods play key role in predicting efficacy of new drugs
November 14, 2018 - Research explores how exercise may help fight drug addiction
November 14, 2018 - Health Tip: Limit Fat, Sugar and Salt in Your Child’s Diet
November 14, 2018 - CA 19-9 Blood Test (Pancreatic Cancer): MedlinePlus Lab Test Information
November 14, 2018 - Old drug could have new use helping sick premature babies
November 14, 2018 - Surgery, not antibiotics, should remain first-line treatment for appendicitis | News Center
November 14, 2018 - Researchers to develop sports-specific classification system for blind football
November 14, 2018 - Preschool children show awake responses to naptime nonsense words
November 14, 2018 - Researchers develop innovative treatment to repair damaged brain tissues
November 14, 2018 - Survey shows negative effect of vulvovaginal atrophy symptoms on quality of life for women
November 14, 2018 - Study sheds light on mechanisms that prevent autoimmune attack
November 14, 2018 - Sleep quality found to be worse for women who undergo surgical menopause
November 14, 2018 - One-hour cognitive behavioral therapy session reduces insomnia symptoms in prisoners
November 14, 2018 - New study provides deeper insight into chromosome segregation during mitosis
November 14, 2018 - Surgical menopause leads to more disrupted sleep than natural menopause
November 14, 2018 - Inhibition of one protein clears toxic clumps seen in Parkinson’s disease, study finds
November 14, 2018 - Appendix removal is linked to lower risk of Parkinson’s
November 14, 2018 - Lifting weights for less than an hour a week may reduce cardiovascular disease risk
November 14, 2018 - Pulmonary rehabilitation rarely received by hospitalized COPD patients despite health benefits
November 14, 2018 - New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers
November 14, 2018 - Regular head circumference assessment of preterm babies can help identify long-term IQ problems
November 14, 2018 - Brigham investigators examine opioid use among Massachusetts adolescents, prescription trends
November 14, 2018 - Study defines biomarker in response to treatment of castration-resistant prostate cancer
November 14, 2018 - Study identifies potential therapeutic strategy for patients with clear cell renal cancer
November 14, 2018 - Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults
November 14, 2018 - Alpha Fetoprotein (AFP) Tumor Marker Test: MedlinePlus Lab Test Information
November 14, 2018 - Researchers evaluate controversial treatment for Parkinson’s disease psychosis
November 14, 2018 - AI could help veterinarians code their notes
November 14, 2018 - Pre-schoolers with autism thrive in mainstream classroom settings
November 14, 2018 - Individual and work-related factors may help promote hospital physician engagement, finds study
November 14, 2018 - Complementary and alternative medicine is widely used by general population in England
November 14, 2018 - Study reveals link between tobacco availability and smoking during pregnancy
November 14, 2018 - Purdue researchers develop translucent base for silicon patches to deliver exact doses of biomolecules
November 14, 2018 - New technology based on moths and magnets could help treat genetic diseases
November 14, 2018 - Concussion-Related Biomarkers Vary Based on Sex, Race
November 14, 2018 - One more year of high school may shape waistlines later in life
November 14, 2018 - Dissecting high drug costs – Scope
FDA Approves Newly Formulated OTC Primatene Mist (epinephrine) to Treat Mild Asthma

FDA Approves Newly Formulated OTC Primatene Mist (epinephrine) to Treat Mild Asthma

image_pdfDownload PDFimage_print

RANCHO CUCAMONGA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (FDA) granted approval of its New Drug Application (NDA) for Primatene Mist (epinephrine inhalation aerosol bronchodilator suspension), which is delivered by a metered dose inhaler (MDI) with a non-chlorofluorocarbon (CFC) propellant. Primatene Mist is the only FDA-approved asthma inhaler available without a prescription in the United States. Primatene Mist is indicated for the temporary relief of mild symptoms of intermittent asthma in people ages 12 and above.

Amphastar’s CEO, Dr. Jack Zhang, stated: “We are very happy to have received FDA approval for Primatene Mist and are proud to bring this important product back to the over-the-counter (OTC) market in the United States. We are grateful to the FDA team for working closely with us to make this approval possible, recognizing the important role of OTC bronchodilator drugs such as Primatene Mist. Amphastar’s mission is to develop and bring to market innovative pharmaceutical products and delivery systems that will meaningfully improve peoples’ lives and we believe Primatene Mist will do just that.”

The newly approved, patented formulation of Primatene Mist is made with the same active ingredient, epinephrine, which was used in the original Primatene Mist before it was removed from the market in 2011 for environmental reasons pursuant to the Montreal Protocol, an important international environmental treaty, which phased out products worldwide containing ozone-depleting CFCs. The product’s new inhalation delivery system no longer includes CFC as the propellant and has other significant new features, including a built-in spray indicator and a metal canister, which replaces the glass container used in the original Primatene Mist product.

According to the Centers for Disease Control and Prevention National Center for Health Statistics, approximately 20 million adults in the United States suffer from asthma. Amphastar is pleased to bring back Primatene Mist as an OTC option for the temporary relief of mild symptoms of intermittent asthma. For more information, visit www.Primatene.com.

Amphastar anticipates that Primatene® Mist will be available in major drug stores across the United States in early 2019.

Pipeline Information

The Company currently has four abbreviated new drug applications (“ANDAs”) filed with the FDA, which are targeting products with a market size of approximately $0.7 billion, three biosimilar products in development targeting products with a market size of approximately $14.0 billion, and 11 generic products in development targeting products with a market size of approximately $12.0 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2018. The Company’s proprietary pipeline includes an NDA for intranasal naloxone. The Company is currently developing four other proprietary products, which include injectable, inhalation and intranasal dosage forms.

Company Information

Amphastar is a specialty pharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation and intra-nasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company’s website at www.amphastar.com.

Amphastar’s logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including DMFs, the timing of product launches and the timing of products becoming available on the market,  acquisitions and other matters related to its current products, pipeline of product candidates and other future events. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov.  Amphastar undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change.

Source: Amphastar Pharmaceuticals, Inc.

Posted: November 2018

Primatene Mist (epinephrine) FDA Approval History

Tagged with:

About author

Related Articles